Zacks.com on MSN2d
The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics
T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
FiercePharma5d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
BioSpace5d
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
Monthly Prescribing Reference1d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Vertex Pharmaceuticals price target lowered to $500 from $503 at JPMorgan
JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $500 from $503 and keeps an Overweight rating on the shares.
Vertex Pharmaceuticals price target raised to $430 from $426 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $430 from $426 and keeps a Sector Perform rating on the shares.
The Pharma Letter5d
Vertex nabs FDA approval for Alyftrek and Trikafta
US drugmaker Vertex Pharmaceuticals’ shares were unmoved on Friday, despite receiving two new regulatory authorizations.